Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 3/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
| ▸ | PI4KA | P42356 | 2/20 | 0.59 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.59 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.59 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.59 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.59 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.59 |
| ▸ | GAPDH | P04406 | 1/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.59 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.59 |
| ▸ | STAT6 | P42226 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | DOT1L | Q8TEK3 | 1/20 | 0.59 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30069724 | 1.00 | ADORA1 (0.62) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL26757815 | 0.90 | ADORA1 (0.77) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL18007468 | 0.90 | ADORA1 (0.77) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL30069767 | 0.90 | ADORA1 (0.77) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL15329279 | 0.90 | ADORA3 (0.71) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL15329393 | 0.87 | ADORA1 (0.64) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL29384896 | 0.87 | ADORA1 (0.64) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL21314872 | 0.87 | ADORA1 (0.64) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL31051048 | 0.87 | ADORA1 (0.81) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B | |
| SCHEMBL27124440 | 0.87 | ADORA1 (0.81) | ADORA1ADORA3SMN1; SMN2PI4KAPI4K2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-12-18 | — | — | US | disclosed |
| US-20250223588-A1 | OLIGONUCLEOTIDES WITH 2'-DEOXY-2'-F-2'-C-METHYL NUCLEOTIDES | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-07-10 | — | — | US | disclosed |
| US-20250188470-A1 | MULTIPLEXING TARGETING LIGANDS THROUGH CLICK CHEMISTRY AT THE ANOMERIC SITE OF SUGARS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-06-12 | — | — | US | disclosed |
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2025-04-17 | — | — | US | disclosed |
| US-20240175028-A1 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | ALNYLAM PHARMACEUTICALS, INC (US) | 2024-05-30 | — | — | US | disclosed |
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | 2023-01-26 | — | — | US | disclosed |
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2021-06-08 | — | — | US | disclosed |
| EP-3693463-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | Alnylam Pharmaceuticals, Inc. (US) | 2020-08-12 | — | — | EP | disclosed |
| EP-3052628-B1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | BANK OF AMERICA, N.A. | 2019-05-16 | — | — | US | disclosed |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | ALNYLAM PHARMACEUTICALS, INC. (US) | 2018-11-06 | — | — | US | disclosed |
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | ALNYLAM PHARMACEUTICALS, INC. (US) | 2016-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160244766-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | ADORA1 3377/4885ADORA3 3185/4885SMN1; SMN2 1851/4885 |
| US-11028392-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | ADORA1 3377/4885ADORA3 3185/4885SMN1; SMN2 1851/4885 |
| US-20260132404-A1 | MODIFIED OLIGONUCLEOTIDES AND DOUBLE-STRANDED RNAS | RNASEL, NSUN2, ADAR | ADORA1 1461/4885ADORA3 859/4885SMN1; SMN2 165/4885 |
| US-20190144870-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | ADORA1 3377/4885ADORA3 3185/4885SMN1; SMN2 1851/4885 |
| US-20230026968-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | ADORA1 3377/4885ADORA3 3185/4885SMN1; SMN2 1851/4885 |
| US-20240175028-A1 | DOSING OF siRNA COMPOUNDS TO THE CISTERNA MAGNA | ELAVL1, HNRNPA1, ELAVL3 | ADORA1 731/4885ADORA3 577/4885SMN1; SMN2 212/4885 |
| US-10119143-B2 | Compositions and methods for inhibiting expression of the ALAS1 gene | AARS1, RNASE1, DDX39B | ADORA1 3377/4885ADORA3 3185/4885SMN1; SMN2 1851/4885 |
| US-20250122505-A1 | COMPOSITIONS AND METHODS FOR INHIBITING EXPRESSION OF THE ALAS1 GENE | AARS1, RNASE1, DDX39B | ADORA1 3377/4885ADORA3 3185/4885SMN1; SMN2 1851/4885 |
| US-20250382324-A1 | MONOMERS AND METHODS FOR SYNTHESIS OF MODIFIED OLIGONUCLEOTIDES | POLM, PCNA, POLRMT | ADORA1 3733/4885ADORA3 3334/4885SMN1; SMN2 613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.